Selank

Selank (Russian: Селанк) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a modified analog of tuftsin (an endogenous immunomodulatory tetrapeptide derived from immunoglobulin G) with an added C-terminal Pro-Gly-Pro stabilizing tripeptide. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. It was registered as a prescription anxiolytic by the Russian Federation Ministry of Health in 2009 and is sold under the brand name Selank in Russian pharmacies as a 0.15 percent intranasal spray.

The molecule was developed by a research team led by N.F. Myasoedov and I.P. Ashmarin in the late 1980s and 1990s. Tuftsin itself (Thr-Lys-Pro-Arg) is a fragment of immunoglobulin G with documented immunomodulatory properties. The Selank modification adds the Pro-Gly-Pro stabilization, which protects the peptide from rapid enzymatic degradation in the nasal mucosa and central nervous system. The result is a compound with both anxiolytic activity (through GABA and serotonin modulation) and immunomodulatory activity (through retained tuftsin-like effects on immune cells).

The molecule was registered by the Russian Federation Ministry of Health in 2009 after clinical trials in generalized anxiety disorder and neurasthenia. It is dispensed as a prescription medication for adults with anxiety and adaptation disorders. Outside Russia, the compound has not been pursued through any major regulatory pathway. There is no FDA approval, no EMA approval, and no MHRA approval. It is widely sold by online research-chemical vendors as "Selank" with "for laboratory use only" labeling.

The Russian Clinical Evidence

The Selank clinical-trial literature is concentrated in Russian-language journals and is not easily accessible to Western reviewers. The most commonly cited trials are:

Zozulia et al. (Zhurnal Nevrologii i Psikhiatrii, 2008). Selank vs medazepam in 62 patients with generalized anxiety disorder and neurasthenia. Both treatments reduced Hamilton Anxiety Rating Scale scores comparably over 14 days. Selank was reported to lack the sedation, cognitive impairment, and withdrawal effects associated with the benzodiazepine. This is the most cited Selank efficacy publication.

Filatova et al. (2017). Confirmatory clinical observations on Selank in anxiety. Reported anxiolytic effect comparable to classical benzodiazepines without sedation or dependence. Smaller study.

Volkova et al. (2016). Documented nootropic activity of Selank with positive effects on memory formation and learning processes, alongside the anxiolytic profile.

A PubMed search for "Selank" returns substantially fewer than 100 results, the majority of which are mechanistic studies in animal models from Russian groups, transcriptomic analyses, and review articles by the original development team. The cumulative human evidence base is smaller than for most Western-developed psychiatric peptides. The trials that exist are generally smaller, shorter, and use different methodology than Western registrational standards.

A 2025 review in Bulletin of Experimental Biology and Medicine summarized the cumulative Russian work, noting effects on transcriptomic patterns in brain cells and ongoing clinical use as an anxiolytic and nootropic drug in Russian medical practice.

Selank's mechanism is multimodal and not fully characterized in Western pharmacological terms.

GABAergic modulation. Selank appears to influence GABA receptor function indirectly, without binding GABA receptors directly. The downstream effect on benzodiazepine-like circuits is what produces the anxiolytic activity. Unlike benzodiazepines, Selank does not produce sedation, cognitive impairment, motor coordination effects, or withdrawal phenomena, which suggests the GABA effect is mediated through different upstream pathways.

Serotonergic modulation. Russian-language publications document effects on serotonin metabolism, including modulation of serotonin turnover in brain regions involved in mood and anxiety. The clinical correlate is anxiolytic activity with possible antidepressant features.

Enkephalin degradation inhibition. Selank reduces the rate at which enkephalins (endogenous opioid peptides involved in pain and anxiety regulation) are degraded. The result is increased availability of endogenous opioid signaling, which may contribute to the anxiolytic effect without producing exogenous opioid-like dependence.

Immunomodulatory activity. The tuftsin-derived structure retains some immune-system effects. Phagocytic activity in macrophages and other immune-cell functions are documented to change with Selank exposure. This is unusual for an anxiolytic medication and is the basis for some claims about combined anxiety-and-immune effects.

The administration route is intranasal in the Russian-approved product. The nasal mucosa provides a pathway for direct CNS delivery through the olfactory pathway and trigeminal nerve, bypassing first-pass hepatic metabolism. Oral bioavailability would be poor due to gastric peptidase degradation.

Regulatory status

Russia. Selank was registered by the Russian Federation Ministry of Health in 2009. It is a prescription anxiolytic available in Russian pharmacies. The intranasal formulation (0.15 percent) is the standard product. The approved indications are generalized anxiety disorder and neurasthenia (a Russian psychiatric category roughly equivalent to mild depression with prominent anxiety).

United States. Selank has no FDA approval. It is not on the FDA Category 2 bulks list as of May 2026, which is unusual for a non-approved peptide and may reflect the smaller commercial footprint compared with peptides like BPC-157 or MK-677. The regulatory position in the US is informal: the compound is widely sold by online research-chemical vendors as a "research peptide" with "for laboratory use only" labeling that the resale ecosystem ignores. Compounding pharmacy availability has historically been limited.

EU and UK. No EMA or MHRA authorization. The compound has not been formally evaluated by major Western regulators despite the Russian approval history.

WADA status. Selank is not currently on the WADA Prohibited List. It is not relevant to typical sport performance and has not been positioned as a performance-enhancing substance.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The Russian clinical-trial data reports a generally clean safety profile. The most consistent findings across published trials are:

Mild headache in a small percentage of subjects, typically transient and self-limited.

Local nasal irritation or transient stinging at administration sites with the intranasal formulation. Generally mild.

No documented sedation at therapeutic doses, which is the most clinically meaningful safety advantage over benzodiazepines.

No documented cognitive impairment measured by standard neuropsychological testing, in contrast to benzodiazepine-class drugs.

No documented dependence or withdrawal phenomena with discontinuation after 14-day courses.

No clinically meaningful drug-drug interactions have been reported in Russian publications. The compound is stated to be compatible with CNS depressants and stimulants, including ethanol, though this should not be interpreted as a recommendation for concurrent use.

The published Western safety data is limited. The compound has not undergone Phase 3 safety trials at the size or duration that Western regulators require for approval. Long-term safety data in healthy adults at chronic dosing is not available.

The comparison most often made is between Selank and benzodiazepines (medazepam, alprazolam, lorazepam). The Russian trial evidence supports comparable anxiolytic efficacy without the sedation, cognitive impairment, motor coordination effects, or withdrawal pattern that defines benzodiazepine pharmacology. If the Russian findings replicate at Western trial rigor (which has not been tested), Selank would represent a meaningful addition to anxiety pharmacotherapy.

The comparison with SSRIs (selective serotonin reuptake inhibitors) is different. SSRIs are first-line for chronic anxiety in Western practice but have a several-week onset, sexual side effects, weight effects, and discontinuation syndrome. Selank has a rapid onset (effects within an hour of intranasal administration in some reports) and lacks the chronic side-effect profile of SSRIs. The two work through different mechanisms and could be complementary in patients who do not tolerate SSRIs.

The Semax comparison is the most natural for the Selank class. Both peptides were developed at the same Russian institute. Both have the same C-terminal Pro-Gly-Pro stabilization. Both are administered intranasally. Selank is the anxiolytic; Semax is the nootropic. They are often combined in adult nootropic protocols, with Selank used for anxiety control and Semax for cognitive enhancement. Combination has not been formally tested in trials.